Log in

Company updateMoneycontrol

Geojit raises Aurobindo Pharma target to Rs 2111

Positive+59

GreyOak summary

Geojit Financial Services retained its BUY rating on Aurobindo Pharma with a revised target price of Rs 2,111. The company reported Q2FY27 revenue growth of 23.9% to Rs 10,263cr, driven by strong performance in formulations and APIs. EBITDA increased 28.5% to Rs 2,156cr with margins expanding to 21.0%.

What it affects

Source

Read the original at Moneycontrol

More Aurobindo Pharma news

All Aurobindo Pharma news →